Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)

被引：0
|
作者：
Nagaiah, G.
Fu, P.
Wasman, J. K.
Cooney, M. M.
Mooney, C.
Afshin, D.
Lavertu, P.
Bokar, J.
Savvides, P.
Remick, S. C.
机构：
[1] Univ Hosp Case Med Ctr, Cleveland, OH USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] W Virginia Univ, Morgantown, WV 26506 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6058
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma.
    Abou-Alfa, GK
    Schwartz, L
    Ricci, S
    Amadori, D
    Santoro, A
    Figer, A
    De Greve, J
    Douillard, JY
    Taylor, I
    Moscovici, M
    Bigwood, D
    Voliotis, D
    Saltz, LB
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9033S - 9033S
  • [2] Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307
    Janne, Pasi A.
    Wang, Xiaofei F.
    Krug, Lee M.
    Hodgson, Lydia
    Vokes, Everett E.
    Kindler, Hedy L.
    ANNALS OF ONCOLOGY, 2006, 17 : 216 - 217
  • [3] Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma:: CALGB 30307
    Janne, P. A.
    Wang, X. F.
    Krug, L. M.
    Hodgson, L.
    Vokes, E. E.
    Kindler, H. L.
    LUNG CANCER, 2006, 54 : S51 - S52
  • [4] Randomized discontinuation trial of sorafenib (BAY 43-9006)
    Jain, Lokesh
    Venitz, Juergen
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2006, 5 (10) : 1270 - 1272
  • [5] A Phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer
    Bianchi, G.
    Loibl, S.
    Zamagni, C.
    Ardizzoni, A.
    Raab, G.
    Siena, S.
    Wolf, C.
    Westermeier, T.
    Bergamini, L.
    Gianni, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [6] First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment
    Maroto-Rey, P.
    Bellmunt, J.
    Trigo, J. M.
    Guillem, V.
    Lopez-Martin, J. A.
    Carles, J.
    Anton-Torres, A.
    Urruticoechea, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [8] Sorafenib (BAY 43-9006) inhibits the growth and angiogenesis of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim, S
    Yazici, YD
    Calzada, G
    Wang, ZY
    Younes, MN
    Jasser, SA
    Myers, JN
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8967S - 8967S
  • [9] Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
    Savvides, Panayiotis
    Nagaiah, Govardhanan
    Lavertu, Pierre
    Fu, Pingfu
    Wright, John J.
    Chapman, Robert
    Wasman, Jay
    Dowlati, Afshin
    Remick, Scot C.
    THYROID, 2013, 23 (05) : 600 - 604
  • [10] A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma
    Uldrick, Thomas S.
    Goncalves, Priscila H.
    Wyvill, Kathleen M.
    Peer, Cody J.
    Bernstein, Wendy
    Aleman, Karen
    Polizzotto, Mark N.
    Venzon, David
    Steinberg, Seth M.
    Marshall, Vickie
    Whitby, Denise
    Little, Richard F.
    Wright, John J.
    Rudek, Michelle A.
    Figg, William D.
    Yarchoan, Robert
    ONCOLOGIST, 2017, 22 (05): : 505 - +
12345